Janus Kinase (JAK) Inhibitors Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Sareum, Chipscreen Biosciences, Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Janus Kinase (JAK) Inhibitors pipeline constitutes key companies continuously working towards developing Janus Kinase (JAK) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Janus Kinase (JAK) Inhibitors Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Janus Kinase (JAK) Inhibitors Market.

The Janus Kinase (JAK) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Janus Kinase (JAK) Inhibitors Pipeline Report: https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Janus Kinase (JAK) Inhibitors treatment therapies with a considerable amount of success over the years.
• Janus Kinase (JAK) Inhibitors companies working in the treatment market are Sareum, Chipscreen Biosciences, Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, and others, are developing therapies for the Janus Kinase (JAK) Inhibitors treatment
• Emerging Janus Kinase (JAK) Inhibitors therapies in the different phases of clinical trials are- SDC-1801, CS-32582, ATI-2138, PF-07295324, EQ-121, CPL409116, TD-0903, Ivarmacitinib, CTP-543, Povorcitinib, and others are expected to have a significant impact on the Janus Kinase (JAK) Inhibitors market in the coming years.
• In March 2023, One of the first once-daily oral selective Janus kinase (JAK) inhibitors, Olumiant® (baricitinib), has been licenced to treat moderate-to-severe active rheumatoid arthritis (RA), atopic dermatitis, alopecia areata (AA), and Covid-19 in adults who are hospitalised and require oxygen support.
• In October 2022, The US Food and Drug Administration (FDA) has approved the Janus kinase (JAK) inhibitor upadacitinib (Rinvoq), for use in adults with non-radiographic axial spondyloarthritis (nr-axSpA), who have objective signs of inflammation, an inadequate response to, or intolerance to, one or more TNF inhibitors, and who also have objective signs of inflammation
• In October 2022, The New England Journal of Medicine (NEJM), according to Incyte, has published data from the important Phase III TRuE-V clinical research programme investigating ruxolitinib cream (OpzeluraTM) 1.5% in patients 12 years of age and older with nonsegmental vitiligo
• In December 2022, A Phase III, double-blind, randomised, placebo-controlled study of the drug povorcitinib (INCB054707) assessed its effectiveness and safety in patients with mild to moderate hidradenitis suppurativa.

Janus Kinase (JAK) Inhibitors Overview
Small compounds called Janus kinase (JAK) inhibitors, with a molecular weight of about 400 Da, can be taken orally. JAKs are phosphotransferases that attach to cytokine receptor intracellular domains and send signals to trigger immune responses.

Get a Free Sample PDF Report to know more about Janus Kinase (JAK) Inhibitors Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Janus Kinase (JAK) Inhibitors Drugs Under Different Phases of Clinical Development Include:
• SDC-1801: Sareum
• CS-32582: Chipscreen Biosciences
• ATI-2138: Aclaris Therapeutics
• PF-07295324: Pfizer
• EQ-121: EQRx
• CPL409116: Celon Pharma
• TD-0903: Theravance Biopharma
• Ivarmacitinib: Reistone Biopharma
• CTP-543: Concert Pharmaceuticals
• Povorcitinib: Incyte Corporation

Janus Kinase (JAK) Inhibitors Pipeline Therapeutics Assessment
• Janus Kinase (JAK) Inhibitors Assessment by Product Type
• Janus Kinase (JAK) Inhibitors By Stage and Product Type
• Janus Kinase (JAK) Inhibitors Assessment by Route of Administration
• Janus Kinase (JAK) Inhibitors By Stage and Route of Administration
• Janus Kinase (JAK) Inhibitors Assessment by Molecule Type
• Janus Kinase (JAK) Inhibitors by Stage and Molecule Type

DelveInsight's Janus Kinase (JAK) Inhibitors Report covers around products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Janus Kinase (JAK) Inhibitors product details are provided in the report. Download the Janus Kinase (JAK) Inhibitors pipeline report to learn more about the emerging Janus Kinase (JAK) Inhibitors therapies at:
https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Janus Kinase (JAK) Inhibitors Therapeutics Market include:
Key companies developing therapies for Janus Kinase (JAK) Inhibitors are - Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., Novartis Pharmaceuticals, Eli Lilly and Company, Kartos Therapeutics, Telios Pharma, Kiniksa Pharmaceuticals, Celgene, GlaxoSmithKline, Abivax S.A., Dizal Pharmaceuticals, Constellation Pharmaceuticals, MaaT Pharma, Galvani Bioelectronics, CTI BioPharma, Crescendo Bioscience, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Astellas Pharma, Imago BioSciences, Geron Corporation, R-Pharm, Almedis LLC, ScienceFiles, Vertex Pharmaceuticals Incorporated, Italfarmaco, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Bristol-Myers Squibb, Cephalon, Karyopharm Therapeutics Inc, and others.

Janus Kinase (JAK) Inhibitors Pipeline Analysis:
The Janus Kinase (JAK) Inhibitors pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Janus Kinase (JAK) Inhibitors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Janus Kinase (JAK) Inhibitors Treatment.
• Janus Kinase (JAK) Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Janus Kinase (JAK) Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Janus Kinase (JAK) Inhibitors market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Janus Kinase (JAK) Inhibitors drugs and therapies-
https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Janus Kinase (JAK) Inhibitors Pipeline Market Drivers
• Rising prevalence of chronic and autoimmune disease, increasing research and development projects for the launch of new drugs are some of the important factors that are fueling the Janus Kinase (JAK) Inhibitors Market.

Janus Kinase (JAK) Inhibitors Pipeline Market Barriers
• However, high cost of treatment, regulatory challenges in the launch of JAK inhibitors and other factors are creating obstacles in the Janus Kinase (JAK) Inhibitors Market growth.

Scope of Janus Kinase (JAK) Inhibitors Pipeline Drug Insight
• Coverage: Global
• Key Janus Kinase (JAK) Inhibitors Companies: Sareum, Chipscreen Biosciences, Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, and others
• Key Janus Kinase (JAK) Inhibitors Therapies: SDC-1801, CS-32582, ATI-2138, PF-07295324, EQ-121, CPL409116, TD-0903, Ivarmacitinib, CTP-543, Povorcitinib, and others
• Janus Kinase (JAK) Inhibitors Therapeutic Assessment: Janus Kinase (JAK) Inhibitors current marketed and Janus Kinase (JAK) Inhibitors emerging therapies
• Janus Kinase (JAK) Inhibitors Market Dynamics: Janus Kinase (JAK) Inhibitors market drivers and Janus Kinase (JAK) Inhibitors market barriers

Request for Sample PDF Report for Janus Kinase (JAK) Inhibitors Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Janus Kinase (JAK) Inhibitors Report Introduction
2. Janus Kinase (JAK) Inhibitors Executive Summary
3. Janus Kinase (JAK) Inhibitors Overview
4. Janus Kinase (JAK) Inhibitors- Analytical Perspective In-depth Commercial Assessment
5. Janus Kinase (JAK) Inhibitors Pipeline Therapeutics
6. Janus Kinase (JAK) Inhibitors Late Stage Products (Phase II/III)
7. Janus Kinase (JAK) Inhibitors Mid Stage Products (Phase II)
8. Janus Kinase (JAK) Inhibitors Early Stage Products (Phase I)
9. Janus Kinase (JAK) Inhibitors Preclinical Stage Products
10. Janus Kinase (JAK) Inhibitors Therapeutics Assessment
11. Janus Kinase (JAK) Inhibitors Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Janus Kinase (JAK) Inhibitors Key Companies
14. Janus Kinase (JAK) Inhibitors Key Products
15. Janus Kinase (JAK) Inhibitors Unmet Needs
16 . Janus Kinase (JAK) Inhibitors Market Drivers and Barriers
17. Janus Kinase (JAK) Inhibitors Future Perspectives and Conclusion
18. Janus Kinase (JAK) Inhibitors Analyst Views
19. Appendix
20. About DelveInsight

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.